IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: Lastly, IL1RAP (also named IL-1R3) blockade, using mAb81.2 and mAb3F8, which induces antibody-dependent cellular cytotoxicity and IL-1 signaling blockade in AML and CML cells provides evidence that IL1RAP may be a potent target in AML cells (33, 193).